Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business merger

Impact Biomedical Zoar Merger Reverse Split Correction

Analysis based on 8 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026

Sentiment
5
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The correction removes uncertainty around the merger exchange ratio, which is modestly positive for Impact Biomedical shares as it clarifies shareholder consideration. However, the reverse split and continued-listing concerns keep the stock speculative, with limited broader market impact given the company's small capitalization.

pharmaceuticals biotechnology

Biomedica. issued a corrected press release on September 14, 2026, fixing the exchange ratio for its proposed merger with Zoar Limited. The original September 11, 2026 release incorrectly stated that Impact stockholders would receive one Zoar Limited share for every four Impact shares; the correct ratio is one Zoar Limited share for every one Impact share held immediately prior to the merger effective time, after giving effect to a reverse stock split. Impact Biomedical's Board of Directors approved a 1-for-12.62 reverse stock split, effective at 12:01 a.m. Eastern Time on September 23, 2026. The stock will continue trading on NYSE American under ticker IBO with a new CUSIP number. Outstanding shares will fall from approximately 107,821,231 to 8,543,679, subject to rounding, with fractional shares rounded up. Stockholders had previously authorized a split range of 1-for-12.48 to 1-for-50 at the CEO's discretion. Equiniti Trust Company will manage the share exchange. The reverse split is intended to support the proposed business combination and continued-listing objectives, though it does not guarantee compliance with NYSE American listing standards or completion of the merger. Zoar Limited has filed a Form F-4 registration statement with the United States — United States Securities and Exchange Commission containing a preliminary proxy statement/prospectus. Upon closing, the combined company is expected to be a pharmaceutical manufacturer focused on active pharmaceutical ingredients, intermediates, formulations, and orphan drug development.

80 Biomedica approved reverse stock split
70 Biomedica corrected merger exchange ratio Zoar Limited
40 Biomedica approved reverse stock split
20 Equiniti Trust Company appointed transfer agent Biomedica
priv
Impact Biomedical is the central entity, correcting its merger exchange ratio and approving a 1-for-12.62 reverse stock split to support its proposed combination with Zoar Limited and NYSE American listing objectives. The clarification reduces uncertainty but the stock remains speculative.
Importance 100.0 Sentiment 10.0
priv
Zoar Limited is the merger counterparty and has filed a Form F-4 registration statement with the SEC. The corrected exchange ratio confirms one Zoar share per Impact share, strengthening the path to completing the business combination.
Importance 85.0 Sentiment 10.0
exch
NYSE American is the listing exchange for Impact Biomedical, which aims to satisfy continued-listing standards through the reverse split. The exchange's listing requirements are a key driver of the transaction.
Importance 30.0 Sentiment 0.0
govactor
The United States — United States Securities and Exchange Commission is the regulator reviewing Zoar Limited's Form F-4 registration statement and the proxy materials for the proposed merger.
Importance 25.0 Sentiment 0.0
priv
Equiniti Trust Company serves as transfer agent managing the share exchange for the reverse stock split, a procedural role with no material financial impact.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.